According to filings with the U.S. Securities and Exchange Commission, Anodyne Nanotech is raising up to $17,259,023.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Anodyne Nanotech
Anodyne is a clinical-stage biotech company simplifying chronic care through a breakthrough in drug delivery. Our proprietary platform, the HeroPatch, is a microneedle patch that delivers multi-milligram doses of biologics, peptides, and monoclonal antibodies through the skin, therapies that previously required injection or IV infusion. Built on solid-state, solvent-free fabrication, the HeroPatch delivers drug loads of up to tens of mg per patch with tunable pharmacokinetic profiles. Stable at room temperature, it eliminates cold-chain logistics and reduces cost up to tenfold versus pen injections. The platform also unlocks next-generation combination therapies, with individual release profiles per molecule. Our pipeline spans a portfolio of programs across obesity, metabolic disease, and beyond, advanced through internal clinical development and strategic external partnerships to maximize the clinical impact and commercial potential of the platform. Anodyne is building a future where complex therapies are easier to access, easier to administer, and easier to live with, for patients and every stakeholder in chronic care.

To learn more, visit https://www.theheropatch.com/
LinkedIn: https://www.linkedin.com/company/hero-patch/

Contact:
Jake Lombardo, President
https://www.linkedin.com/in/jake-lombardo/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.